239 related articles for article (PubMed ID: 33876553)
1. Aqueous eye drops containing drug/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment.
Loftsson T; Stefánsson E
Acta Ophthalmol; 2022 Feb; 100(1):7-25. PubMed ID: 33876553
[TBL] [Abstract][Full Text] [Related]
2. Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye.
Loftsson T; Stefánsson E
Int J Pharm; 2017 Oct; 531(2):413-423. PubMed ID: 28391041
[TBL] [Abstract][Full Text] [Related]
3. Topical dexamethasone-cyclodextrin nanoparticle eye drops for non-infectious Uveitic macular oedema and vitritis - a pilot study.
Shulman S; Jóhannesson G; Stefánsson E; Loewenstein A; Rosenblatt A; Habot-Wilner Z
Acta Ophthalmol; 2015 Aug; 93(5):411-415. PubMed ID: 25988730
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans.
Kristinsson JK; Fridriksdóttir H; Thórisdóttir S; Sigurdardóttir AM; Stefánsson E; Loftsson T
Invest Ophthalmol Vis Sci; 1996 May; 37(6):1199-203. PubMed ID: 8631635
[TBL] [Abstract][Full Text] [Related]
5. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops.
Loftsson T; Hreinsdóttir D; Stefánsson E
J Pharm Pharmacol; 2007 May; 59(5):629-35. PubMed ID: 17524227
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure.
Lorenzo-Soler L; Olafsdottir OB; Garhöfer G; Jansook P; Kristinsdottir IM; Tan A; Loftsson T; Stefansson E
Acta Ophthalmol; 2021 Jun; 99(4):376-382. PubMed ID: 33191620
[TBL] [Abstract][Full Text] [Related]
7. Cyclodextrin-poloxamer aggregates as nanocarriers in eye drop formulations: dexamethasone and amphotericin B.
Jansook P; Pichayakorn W; Muankaew C; Loftsson T
Drug Dev Ind Pharm; 2016 Sep; 42(9):1446-54. PubMed ID: 26765786
[TBL] [Abstract][Full Text] [Related]
8. γ-Cyclodextrin nanoparticle eye drops with dorzolamide: effect on intraocular pressure in man.
Gudmundsdottir BS; Petursdottir D; Asgrimsdottir GM; Gottfredsdottir MS; Hardarson SH; Jóhannesson G; Kurkov SV; Jansook P; Loftsson T; Stefánsson E
J Ocul Pharmacol Ther; 2014 Feb; 30(1):35-41. PubMed ID: 24205991
[TBL] [Abstract][Full Text] [Related]
9. Development of a cyclodextrin-based aqueous cyclosporin A eye drop formulations.
Jóhannsdóttir S; Jansook P; Stefánsson E; Loftsson T
Int J Pharm; 2015 Sep; 493(1-2):86-95. PubMed ID: 26220650
[TBL] [Abstract][Full Text] [Related]
10. Topical drug delivery to the eye: dorzolamide.
Loftsson T; Jansook P; Stefánsson E
Acta Ophthalmol; 2012 Nov; 90(7):603-8. PubMed ID: 22269010
[TBL] [Abstract][Full Text] [Related]
11. yCD/HPyCD mixtures as solubilizer: solid-state characterization and sample dexamethasone eye drop suspension.
Jansook P; Ritthidej GC; Ueda H; Stefánsson E; Loftsson T
J Pharm Pharm Sci; 2010; 13(3):336-50. PubMed ID: 21092707
[TBL] [Abstract][Full Text] [Related]
12. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye.
Loftsson T; Stefánsson E
Acta Ophthalmol Scand; 2002 Apr; 80(2):144-50. PubMed ID: 11952479
[TBL] [Abstract][Full Text] [Related]
13. Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema.
Ohira A; Hara K; Jóhannesson G; Tanito M; Ásgrímsdóttir GM; Lund SH; Loftsson T; Stefánsson E
Acta Ophthalmol; 2015 Nov; 93(7):610-5. PubMed ID: 26201996
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone eye drops containing γ-cyclodextrin-based nanogels.
Moya-Ortega MD; Alves TF; Alvarez-Lorenzo C; Concheiro A; Stefánsson E; Thorsteinsdóttir M; Loftsson T
Int J Pharm; 2013 Jan; 441(1-2):507-15. PubMed ID: 23149258
[TBL] [Abstract][Full Text] [Related]
15. Topical noninvasive retinal drug delivery of a tyrosine kinase inhibitor: 3% cediranib maleate cyclodextrin nanoparticle eye drops in the rabbit eye.
Lorenzo-Soler L; Praphanwittaya P; Olafsdottir OB; Kristinsdottir IM; Asgrimsdottir GM; Loftsson T; Stefansson E
Acta Ophthalmol; 2022 Nov; 100(7):788-796. PubMed ID: 35080812
[TBL] [Abstract][Full Text] [Related]
16. Drug delivery to the posterior segment of the eye.
Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
[TBL] [Abstract][Full Text] [Related]
17. A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation.
Wong CW; Metselaar JM; Storm G; Wong TT
Br J Ophthalmol; 2021 Dec; 105(12):1617-1622. PubMed ID: 33127826
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C
Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid.
Jóhannesson G; Moya-Ortega MD; Ásgrímsdóttir GM; Lund SH; Thorsteinsdóttir M; Loftsson T; Stefánsson E
Acta Ophthalmol; 2014 Sep; 92(6):550-6. PubMed ID: 24373641
[TBL] [Abstract][Full Text] [Related]
20. Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration.
Sigurdsson HH; Stefánsson E; Gudmundsdóttir E; Eysteinsson T; Thorsteinsdóttir M; Loftsson T
J Control Release; 2005 Jan; 102(1):255-62. PubMed ID: 15653150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
